Celularity 批准 10 换 1 的反向股票分割。 Celularity approves 1-for-10 reverse stock split.

生物技术公司 Celularity 已批准对其 A 类普通股进行 10 比 1 的反向股票分割，以提高其股价并满足纳斯达克上市要求。 Biotech company Celularity has approved a 1-for-10 reverse stock split of its Class A common stock to boost its share price and meet Nasdaq listing requirements. 此次分拆将于2024年2月28日生效，并于2024年2月29日在分拆调整后的纳斯达克资本市场开始交易。 The split will take effect on February 28, 2024, and trading will begin on the Nasdaq Capital Market on a split-adjusted basis on February 29, 2024. 该公司股票周五常规交易收盘上涨 7.1%，至 46 美分。 The company's stock finished Friday's regular session up 7.1% at 46 cents.